Scott Dunseth Myers, President and CEO at Cascadian Therapeutics, Inc. (CASC), bought 20,500 shares at $3.76 ($77K) on 2017-01-27, disclosed to the SEC on 2017-01-31.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Clearly above the average filing.
| Filing → |
| VRDN | BUY | 2023-04-12 | $101K | — | Filing → |
| VRDN | BUY | 2023-03-13 | $160K | — | Filing → |
| CASC | BUY | 2017-08-14 | $21K | — | Filing → |